

COMPANY

International Milk Bank,
DBA of IMB, Inc. NV Corp 2014
Only The Breast, Inc. NV Corp 2012
internationalmilkbank.com
onlythebreast.com

IMB is a human milk bank,
processing nutritionally
standardized human milk for
Preemie and Full Term Infants.

Contact: Glenn Snow

gssnow@imilkbank.com
Office (775)364-0760
Direct (925) 297-7967

Industry

Category: Bio-Pharma/Nutrition
Human Milk Supplier

Financing Sought

Seeking 17,000,000
Open to Debt/Equity investments

Use Of Proceeds

Round (1) \$5M - Facility acquisition,
engineering, Exec onboarding, Dept
developments

Round (2) \$7M - Equip, FDA, Permits

Round (3) 5M - 2017 Working Capital

Expansion Strategy

Supply the US standard milk shortage
Expand the supply to unserved market
segments: Mid-Term, Late-Term Preemies
Major Research Studies
Deploy international milk banks


Exit Strategy

IMB is open to acquisition or
IPO with the right market timing.



Executive Summary

International Milk Bank, dba IMB, Inc. (IMB) is setting a new industry standard for Human Milk Processing. The demand outpaced the supply until IMB partnered with Only The Breast, Inc. (OTB) answering the U.S. Surgeon General's cry to "build a national strategy and efficaciously resolve the shortage for such a vulnerable population". IMB pioneered the breast milk marketplace with OnlyTheBreast.com, the largest breast milk donor community in the world. OTB has over 87,000,000 oz. annually and donors skyrocketing with 2500 + new members per month. Together IMB can provide more milk than all other milk banks combined and will meet international regulations with a Pharmaceutical Grade Good Manufacturing Practices Plant. IMB will make natures gold standard for nutritional care to every baby, every need, everywhere.



OPPORTUNITY / MARKET DEMAND

Today, breast milk is the standard of care for pre-term infants as endorsed by the American Pediatric Association. Scientific research has shown irrefutably, that feeding only human milk to pre-term babies is not only medicinal but also critical. **The U.S. breast milk demand is approximately 72,000,000 oz. annually with only 8,000,000oz currently supplied.** This leaves a deficiency of 64,000,000 ounces and steadily increasing. Translated this leaves millions of pre-term babies subject to life threatening disease, birth defects, recurring health issues from lack of antibodies, growth and development deficiencies from undernourishment, and a monumental increase in life long medical expenses. These volumes don't begin to touch the expanding need to those whose mom's cannot nurse or have no access to human breast milk. That segment relates to 621 million ounces more. The International demand begins with 200,000,000 ounces' a void that is just waiting to be filled. Answering this need, International Milk Bank (IMB) has created a process that works. With over 51,000 nursing mothers available waiting to donate milk to other babies in need, IMB is ready to make that desire come true.

U.S. Market – Begins @ 72,000,000 oz.

Our initial target is to meet the needs of babies in the Neonatal ICUs providing safe, 20 cal/oz standardized milk. NICU's are an established market, with a systemized delivery, providing the quickest entry for production and revenue. Hospitals as the purchasing agent have a clear expectation of the need. IMB's upgraded product supply, and with their solvent sophisticated purchasing process can make a prompt cash settlement.

There is yet another 2 million babies in need that are presently outside the eligible cut off at 32 weeks. These babies are presently doing without. However, due to the volume of milk IMB can produce, we can not only serve those but a much larger market. Research shows there is another 621 million ounces of potential market volume waiting to meet the needs of these infants. This equates to a \$5.5 Billion opportunity. IMB's goal is in meeting the immediate need of the most premature babies, expanding the benefits to those babies 33 weeks and beyond to full term and bringing greater benefit to the outpatient market.

INTERNATIONAL – 200,000,000 oz

After meeting US Demands, IMB will expand their services to international shores to address the glaring needs of many other countries. With our cGMP pharmaceutical grade facility, our safe, stable milk products requiring no refrigeration, and the unprecedented supply of donor breast milk, we are confident the international market will be a fulfilling and sustainable one.

98% of The Potential Market is Not Being Served


Unserved Market

Only 8M Oz. Served to Most Premature Segment

Unserved US Market Potential Volume= 621M Oz.

Unserved US Market Opportunity = \$5.5 Billion

US Preemie Opportunity = 71M Oz = 2.2 Billion



IMB Is Focused on reaching all Markets!



Competitive Advantage

IMB has acquired Only The Breast, the world's largest supply of Human breast milk, along with exclusive licensing agreements that will launch IMB's safe milk products to the front of the purchasing line. This advantage ensures market position, longevity and profitable growth as we capture 80% of the market share and solve the supply problem. The future of milk banking is found online. OTB holds top positions for all relevant key words controlling the majority of the industry specific search engine results, thereby solidifying our market lead and future industry dominance and will continue to capture the Internet milk bank landscape.

Coupled with our GMP large volume facility, the nutrient rich donor milk products with a co-packaged product line, IMB is positioned head and shoulders above any competitor. We will set a new standard of human milk processing and delivery. With no FDA regulating 'event' or required clinical trials, we can go straight to market. IMB operates in accordance with FDA and international regulatory standards, thus eliminating consumer concerns and setting the stage for a seamless International expansion.

Exclusive Supply Advantage



OTB is Exclusive to IMB!

- Unprecedented Supply
- 2500 New Donors Monthly
- **87.7 Million Ounces Annually**

Our Secret to Success:

We serve the mothers needs so they can serve the babies needs!

Internationalmilkbank.com

Competition

IMB market participants are Human Milk Banking Association of North America (HMBANA), Prolacta Bioscience, and Medolac Laboratories, and yet with their combined supply efforts selling every ounce they are able to produce. This clearly states that participating milk banks have not touched the demand and distinguishes the availability for IMB to position themselves as main suppliers.

HMBANA is an association of individual non-profit milk banks operating to serve the human milk needs in North America. As of 2014, HMBANA banks have a combined volume of 3.5 million ounces. These small banks have a high-risk milk supply as they do not employ milk screening for drugs, pharmaceuticals, adulteration, and pasteurize their donated milk. They are unable to meet a fraction (5.2%) of the national demand, and due to their business model and size, eliminates them from any national modernization opportunities.

Prolacta Bioscience primary focus remains on fortifying human donor milk because of the high profit margins (\$180/oz) for such a product. They supply donor milk equivalent to the sales of their human milk fortifier, thus limiting the available supply. Prolacta Capital partners have invested over \$46 M for research, clinical trials achieving FDA approvals on their milk product fortifiers and their manufacturing facility. This investment truly prohibits them 'switching' from a pasteurization processes which is the foundation of their main formulary product, to the more safe and advanced sterilization method. Their narrow focus on high profit formulary products results in a constriction of milk supply driving a further demand for their product lines but still only supplying 5% of the national deficit.

Medolac Laboratories founded by Elena Medo, also the previous founder of Prolacta Bioscience, employs a sterilization process for human milk to answer the pasteurization problem now eradicating *Bacillus Cereus*. However, Medolac clearly states their focus is on research and development of components, operates out of a small 4000 sq. ft. process facility and produced less than 2% of the national milk need in 2014. The FDA classifies Medolac Laboratories as a 'formulary company' requiring lengthy, expensive clinical trials proving fortified milk products, just like Prolacta. This narrow focus results in expensive formulary products and less human donor milk available to meet the national deficit and leaving a vulnerable population at risk. Neither of these companies is focused or able to significantly reduce the 72,000,000 oz. need. Medolac is currently in litigation filed by Prolacta claiming she 'absconded with proprietary client information while at Prolacta.' That is not the end of Medolac's problems as of June 2015, Mother's Milk Coop, owned by Medolac, and supplies the company with donor breast milk, is now being sued for Trademark infringement from Mother's Milk, a company called Traditional Medicinal since 1980, who holds the 35 year old trademark for 'Mother's Milk' and claims Medolac cannot have a consumer product for sale with the same name. Medolac has laid off most of their staff, and other professional relationships are contacting IMB for safe human milk.



Milk Products and Benefits

Addressing the growing demands of the human milk marketplace with safe innovative solutions, IMB's human milk products are co-packaged with essential organism's. They are available in a bioavailable form and are safe from contamination, disease and rich in natural nutrients, preserving donor human milk in its most natural form. Nutritional values are standardized, and products are developed with convenience and price in mind.

Serving the hospitals needs first, IMB will expand to an outpatient market, starting with discharged infants who need donor human milk as a supplementation to continue progressing, as well for mothers who cannot or choose not to breast feed but understand the life giving benefits. We will utilize direct Internet sales to retail customers. Our products and services are structured to serve National and International markets.

IMB Milk Products are comprised of 100% human donor milk.

- Ready to Feed in 2 & 4 oz servings
- Contain protein, fat, and calories derived only from sterilized donated human milk
- Bioavailable for digestibility and nutrient absorption
- Free from bacteria, drugs, disease or adulterations
- At or above American Academy of Pediatric nutritional recommendations



With the variety of standardized products offered at lower price points, hospitals that would never be able to serve even the smallest population can afford to do so. We will not only serve the millions of babies in need, but broaden IMB's market without resistance. No other competitor is providing enough volume at competitive pricing allowing other premature or full-term babies to realize the increased health and long term benefits of thriving on Safe Human breast milk.

Marketing Mix

International Milk Bank will revolutionize the sale and distribution of human milk through a variety of methods. With such a large volume of donor milk available, IMB will become the first to actually meet the national deficit and expand distribution internationally. Today's Internet advantage is a large pathway into marketing a business, product, or building public awareness. Mr. Snow's proven methodologies for Search Engine Optimization and the marketing benefits are depicted in Only The Breast position, volume, and network.

Thus, IMB will employ the SEO success of OTB and optimize the Internet in various forms directing marketing campaigns towards public awareness on the benefits, safety, and the standardization of human milk.



Only The Breast has been featured in 100's of national publications.

Distribution and Promotion


IMB has established relationships with the nation's largest hospital supply chain organizations. The response was overwhelming as there has never been a safe donor milk supply large enough to utilize this distribution method, in which they are creating a category specific to breast milk that will trigger marketing awareness, education, and orders from the various hospitals they serve. IMB will be distributing through Novation, which supplies more than 2,700 hospitals; Children's Hospital Association, which supplies 54 healthcare systems; and GHX, a modernized software system that enables electronic purchasing and quick payment in volumes for hospitals and healthcare professionals. This modern far-reaching approach will streamline the ordering, invoicing and payment process and eliminate outdated, time-consuming and costly milk-ordering processes that seem to have stymied milk banks for 40 years. The GHX system serves more than 4,000 hospitals to distribute IMB's milk to meet the most at-risk infant population nationwide. The cost of their marketing and distribution services is 3-4% of product sales. Our competitors have not been able to utilize this channel due to their business model, selling only enough milk to mix with their formulary additives.

IMB will offer introductory marketing campaigns that target neonatal intensive care units offering attractive pricing for volume purchases. IMB clearly understands the procurement needs of today's hospitals. Thus we are providing per-ounce pricing at 40% less than our competitors rate. Not only will our customer realize a naturally standardized nutritional milk product, but due to the packaging and extended shelf life, they will be able to keep inventory on hand without risking the investment due to a short product life.

Market Opportunity Break Down


| Category | Customer Base | Oz Per Customer | Total Oz. Demand | Oz. Served | Oz Opportunity | Oz Average Price | Market Opportunity |
|-------------------------|---------------|-----------------|------------------|------------|----------------|------------------|--------------------|
| <32 | 75,537 | 352 | 26,589,024 | 8,000,000 | 18,589,024 | \$22.00 | \$408,958,528.00 |
| 32-36 Weeks | 147,798 | 240 | 35471520 | 0 | 35471520 | \$22.00 | \$780,373,440.00 |
| 32-36 Preemie Fortifier | 221,279 | 80 | 17702320 | 0 | 17702320 | \$60.00 | \$1,062,139,200.00 |
| Cesarean | 771,494 | 336 | 259221984 | 0 | 259221984 | \$6.00 | \$1,555,331,904.00 |
| Full Term | 865,080 | 336 | 290666880 | 0 | 290,666,880 | \$6.00 | \$1,744,001,280.00 |
| Totals | 2,081,188 | | 629,651,728 | 8,000,000 | 621,651,728 | | \$5,550,804,352.00 |

≤32 Very Early Market




\$408 Million

32-36 Preemie Market




\$1.8 Billion

Cesarean Market



\$1.5 Billion

Full Term Market



\$1.7 Billion

IMB will expand the available milk supply to unmet market segments

Achievements

- Patent Estate(s) – In process
- Trade Secret(s) - Developing
- Trademark(s) - Filed
- Exclusive Licensing Agreements
- Co-packaging agreements
- Manufacturing Facility 95,000SQFT
 - Phase 1 Capacity 50M Oz. Year
 - Phase 2 Capacity 100m Oz. Year
- Expanded marketing segments & Financial Opportunities – Hospital, WIC, Out-Patient FDA Validation
- Master Plan in Development
- Key Executive Leadership
- OTB Milk supply acquisition
- Advanced Milk Product Lines
- PEO – Executive/Staff recruitment
- P2i ~ Global Marketing Opportunity
- Novation & Ni-Q Distribution Networks
- **IMB 2015 Spotlight:** CNN, Newsweek, BBC, New York Times, Associated Press, Milk Genomics, Daily Mail, Telegraph, RGJ and multiple other national and international interviews

Financial Request - \$17,000,000

International Milk Bank is seeking and investment partner with a potential combination of debt and equity if needed.

- **FY 1 - Ramp Year** - Pharmaceutical Grade Facility (GMP) meeting International standards
 - **Round (1) \$5M** - Facility acquisition, design/build engineering & 20% Equipment deposits, Executive Onboarding, departments develop, recruiting, FDA validation prep
- **Round (2) \$7M** - FDA Validation, Equipment Install & Integration
- **Round (3) \$5 M** - Product Acquisition & Sales, General Admin \$ Mfg Ops



5 Year Projections

| Oz. Sold | Ramp/FY 1 2016 | | FY 2 2017 | | FY 3 2018 | | FY 4 2019 | | FY 5 2020 | | FY 6 2021 | |
|---------------------------|----------------|------------------|-----------|-------------------|-----------|-------------------|-----------|--------------------|-----------|--------------------|-----------|--------------------|
| | | 222,297 | | 1,976,019 | | 3,946,428 | | 7,562,854 | | 11,433,288 | | 18,484,862 |
| Standard 20 | \$ | - | \$ | 3,111,507 | \$ | 8,980,052 | \$ | 15,818,719 | \$ | 22,957,679 | \$ | 37,117,014 |
| Preemie 20-26 | \$ | 2,406,773 | \$ | 24,988,358 | \$ | 44,204,997 | \$ | 78,172,369 | \$ | 120,696,045 | \$ | 193,068,705 |
| Preemie +4 | \$ | - | \$ | 10,345,737 | \$ | 22,150,796 | \$ | 50,619,901 | \$ | 76,525,595 | \$ | 123,723,381 |
| Total Revenues | \$ | 2,406,773 | \$ | 38,445,601 | \$ | 75,335,846 | \$ | 144,610,989 | \$ | 220,179,319 | \$ | 353,909,101 |
| Cost of Goods Sold | \$ | 1,395,163 | \$ | 6,356,167 | \$ | 12,481,389 | \$ | 24,964,833 | \$ | 38,060,084 | \$ | 60,582,280 |
| Gross Profit | \$ | 1,011,610 | \$ | 32,089,434 | \$ | 62,854,456 | \$ | 119,646,156 | \$ | 182,119,235 | \$ | 293,326,821 |
| Expenses | | 6,771,055 | | 8,222,542 | | 11,424,451 | | 12,027,004 | | 12,941,571 | | 13,739,138 |
| GP % | | 42% | | 83% | | 83% | | 83% | | 83% | | 83% |
| Earnings, (EBIT) | \$ | (5,759,445) | \$ | 23,866,891 | \$ | 51,430,005 | \$ | 107,619,152 | \$ | 169,177,664 | \$ | 279,587,683 |

| USE OF PROCEEDS | Ramp Up Yr 1-2 | Rnd (1) \$5M | | Rnd (2) \$7M | | Rnd (3) \$5M | | Rnd 2b |
|---|----------------------|---------------------|---------------------|---------------------|---------------------|--------------|-------------------|-----------|
| | | 1st Qtr | 3rd Qtr | | | Y2 1st Qtr | EQUIPMENT (LOAN) | |
| Facility & Equipment | | | | | | | | |
| Quality | 820,000 | | 328,000 | \$ | 492,000 | | | |
| FDA Validation | 1,282,500 | | | \$ | 1,282,500 | | | |
| Manufacturing Equipment | 4,660,000 | \$ | 1,398,000 | | 1,398,000 | | \$ | 1,864,000 |
| cGMP Facility Engineering | 250,000 | \$ | 250,000 | | | | | |
| IT Software/Hardware | 250,000 | | 125,000 | | 125,000 | | | |
| Fed/State/Local Permits | 343,500 | | 171,750 | | 171,750 | | | |
| Feasibility & Stability Eval | 100,000 | | | | 100,000 | | | |
| Facility Fit Up | 675,000 | \$ | 135,000 | | 270,000 | | | 270,000 |
| Total Equipment & Fit Up costs | \$ 8,381,000 | \$ 2,407,750 | \$ 3,839,250 | \$ - | \$ 2,134,000 | | | |
| | | | | | | | | |
| Direct Cost of Goods Yr 1 | \$ 1,395,163 | | | \$ 209,274 | \$ 1,185,889 | | | |
| Acquisition 1st Qtr Year 2 | \$ 1,589,042 | | | \$ 556,165 | \$ 1,032,877 | | | |
| Total Acquisition Costs | \$ 2,984,205 | | | \$ 765,439 | \$ 2,218,766 | | | |
| | | | | | | | | |
| Manufacturing Operations | \$ 1,438,361 | | | \$ 863,017 | \$ 575,344 | | | |
| Sales & General Administrative Costs | \$ 1,355,178 | \$ | 338,795 | \$ 338,795 | \$ 677,589 | | | |
| Onboarding Department Staff | \$ 1,799,599 | \$ | 449,900 | \$ 449,900 | \$ 899,800 | | | |
| Brokerage Fees 10% (If Applicable) | \$ 1,700,000 | \$ | 500,000 | \$ 700,000 | \$ 500,000 | | | |
| SG & A Totals | \$ 6,293,138 | \$ 1,288,694 | \$ 2,351,711 | \$ 2,652,733 | | | | |
| | | | | | | | | |
| Donor Nutritional Project | \$ 250,000 | \$ | 250,000 | | | | | |
| Provisional Patent Filings | \$ 100,000 | \$ | 100,000 | | | | | |
| Licensing Clinical Trials UC Davis | \$ 300,000 | \$ | 300,000 | | | | | |
| Non-Tangible Assets | \$ 650,000 | \$ 650,000 | | | | | | |
| | | | | | | | | |
| Facility Lease and TI Prepads | \$ 544,544 | \$ | 544,544 | | | | | |
| TOTAL FOR 2 YEAR RAMP | \$ 18,852,887 | \$ 4,890,988 | \$ 6,956,400 | \$ 4,871,499 | \$ 2,134,000 | | | |

Milestones

Fiscal Year 1 - 1-3 Mo

- Facility acquisition, cGMP engineering, prepaids
- Mfg. Equipment deposits, ordered
- Certifications: Financials, Processing
- Donor nutritional Project
- Clinical trials with Biotherapeutics exclusive
- Executive, Management, onboarding
- IMB Department development (11)
- IP- Patent Library expansion

Fiscal Yr 1 - 4-6 Mo

- IMB Department implementation
 - Systems, processes, integration
 - Procedures, protocols, deliverables
- Government Affairs advocacy launch
- Facility Leasehold Fit up - CMA leadership
- Donor CSR Development, staffing
- Marketing Campaign; expand Hospital pipeline, contracts
- Staffing, SOP Training

Fiscal Yr 1 - 7-12 Mo

- Manufacturing processing
 - Donor testing, acquisition, processing milk
- Facility Commissioning – Beta testing
- Viable product sales
- Expand marketing & sales pipeline
- Legislative maneuvering; insurance, state recognition
- Scale to full milk production
- Launch Exclusive co-packaging
- Capture market share

Executive Leadership Team

IMB Leadership team possess exceptional skills and talents in business they demonstrate total mastery in every requisite area within this industry; Proven experience, credentialing with characteristics that spell success.

Management Bio's



Glenn Snow - CEO and Founder

As the founder, architect and developer of International Milk Bank and OnlyTheBreast.com, Glenn is an expert in breast milk processing, donating, testing, sharing and modern milk banking. As an industry insider, Glenn has been driving positive changes in milk banking for over 6 years. With a strong background in market development, internet sales, SEO, web development, sales psychology he was able to successful launch Only The Breast Inc., and successfully accomplish his goals creating a platform that can bring a solution to this industry.

Co-Founder of Only The Breast Inc.

Through Onlythebreast.com (OTB), the world's first and largest online breast milk marketplace, Glenn has disrupted the human milk banking industry and taken 80% market share by facilitating the vast majority of online sales of human milk. Glenn has grown OTB to have 5 times the access to human milk than all competing milk banks combined, and dominates organic search results with top placement in all applicable search categories.

Before entering the human milk arena his previous entrepreneurial experience includes real estate investing and the co-founding of the tech company Eftheon which developed an advanced PC operating and encryption system. Eftheon later pivoted into Internet Placement Specialists which was at the forefront of SEO industry providing cutting edge SEO services. This startup and SEO experience proved to be a key to success for future development of OTB. Between Eftheon in 2003 and OTB in 2009 Glenn became a successful real estate investor building a multimillion dollar portfolio.



Michael Shirley – General Manager- Operations

Michael Shirley brings 20+ years of operations experience in the pharmaceutical, dietary supplement and infant formulation industries to the executive team of International Milk Bank. Mr. Shirley earned a master's degree in pharmaceutical science from Rutgers University, and has since held roles of increasing responsibility in the formulation, development, processing and distribution of various product forms.

As an executive, Mr. Shirley has an impressive track record in strategic planning, business unit development, project, and product management. As the former Director of

Operations for Prolacta Bioscience, IMB's primary competitor, Mr. Shirley was responsible for the manufacturing and distribution of human breast milk-based formulations specifically designed for pre-mature infants. He scaled to fit an expansion of Prolacta's daily production from a 32,000 to a 68,000 facility focusing on process improvement and streamline productive flow improving the turnaround cycle of time from donation to deliverable product. Mr. Shirley's hands-on experience in the handling and processing of human breast milk, combined with his demonstrated ability to lead diverse teams of professionals to new levels of success, are key elements in the success of International Milk Bank.

His executive experience incorporates the development of NOW Foods initiating start up and ongoing day -o-day operations. Mr. Shirley was VP/GM for Aaron Industries Inc., where he lowered processing costs, improved market share with strategic pricing opportunities as he restricted the process/design and manufacturing of OTC liquid product a \$70 million operation.

Directors

Quality Assurance Director, Wanda Coulombe

SQF PRACTITIONER, HACCP CERTIFIED, BA Biological Sciences

20 years' experience managing Quality and Food Safety, and customer and technical service functions in the dairy industry-milk, whey, cheese, ice cream, butter and yogurt. This involved managing Quality, Food Safety and all activities at several plant locations in terms of staffing, budgets, purchasing, planning, sanitation and testing, reporting, writing and implementing procedures. Assure quality products through continuous improvement of quality systems including HACCP, SSOPs, cGMPs, Integrated Pest Management, and food safety training. Developed, maintained, and executed clearly defined Quality Assurance Programs to achieve and sustain ISO-FSSC 22000 certification enabling company to reestablish business with major distributors. Evaluate and audit the quality of system design, processes, materials, deliverable products and acceptance or rejection to assess and ensure compliance with internal policy and procedures in compliance to SQF and ISO standards.

Quality Control Director, Craig Setter

BS CLS(NCA) MT(ASCPcm)

In his 18 year laboratory career Craig has amassed 16 years management experience and 15 years' experience as a Quality Control Officer. He has opened 5 labs, 3 from bare walls, including Medical, Veterinary and Forensic Toxicology laboratories. Proven in very tightly regulated laboratories with DOD, FBI and CIA contracts where he learned quality control methods. Experience with the following: Method development, QA/QC, SOP writing, manual and automated chemistry, hematology, immunology, serology, urinalysis, toxicology, fluorimetry, densitometry, immunoblot, Southern and Western blot, DNA sequencing, molecular diagnostics, PCR, qPCR, rtPCR, ELISA, RIA, viral /bacterial /mammalian cell culture, extraction and purification, flow cytometry, electroporation, micro-plating, and microscopy. Laboratory administrative: budgeting, cost projections, analysis (COG/ COS/ ROI etc.), taxation, billing/ collections, insurance billing, Medicare billing, CPT coding, and customer relations and retention.

Validation Director, Cathelene Compton

CMQ/OE, ASQ Certified, HACCP Certified, MS Business Management, BS Biological Sciences

Ms. Compton possesses an in-depth knowledge of all aspects of validation from equipment/facilities qualifications, method validation, cleaning validation and process validation. This knowledge has been obtained through her over nineteen years of experience in Quality Assurance in the ethical and pharmaceutical products, medical devices, as well as nutritional supplement products, industries. She has developed multifaceted validation program experience dealing with new product introductions for pharmaceutical, biotechnology, aseptic processing, new packaging systems, manufacturing systems and facilities. Her experience in quality system development, coupled with her experience in auditing, provides clients with a strong foundation for these programs.

Manufacturing Director, Wayne P McKay

Over 30 years' Experience, 7 plant startups that covers plant size from 5,000 sq. ft. to 200,000 sq. ft., Plant design, Production Equipment Purchasing and installation. Developing and writing of Plant S.O.P. Highly involved with machine and system purchasing and installation, training of system from start to validation of equipment that falls within FDA regulations. Overseen the selection and awarding of contracts to Electrical and Construction Contractors from the start to completion within Pharmaceutical industry. With years of manufacturing I have developed, written and trained manufacturing plants with Maintenance P.M. Programs, Safety Programs, Plant Evacuation Programs, Team Building Programs along with Production Flow Design and Development.

FDA Validation - Risk Mitigation Team



*Cleanroom® Management
Associates Incorporated*

**Filtration
Technology Inc.**

**Filtration &
Contamination Control
Specialists**



Richard Matthews
Facility



Karen McCulloug
Labs



Anne Marie Dixon

Contamination control expert

- FDA industry expert
- Head of US delegation to ISO TC 209
- Chairs 4 standards committees
- ISO 9000 auditor
- 14 books published
- Over 400 technical articles
- 38 years experience



Bob Zeid
Equipment-Cleaning
Prevention-Quality



Scott Kemp
Validation



Advisory Board

Key Scientific Advisors:

Professor Bruce German Director Foods For Health Institute - UC Davis

John Tompkins, FDA-compliant processing engineering and milk processing

Industry Advisors:

Robin Hollen, M.Ed., RN, IBCLC, RLC, FILCA

Rebecca Perry, MD, Neonatal-Perinatal Medicine

Catherine Wagoner, M.D., F.A.A.P.

Dave Dallas, PhD Nutritional Biology, Postdoctoral Researcher – UC Davis

Craig Macy, Management and Technology Strategist, I.P. Lawyer

Professor Doug Redelman, Ph.D. Molecular Biosciences Director- UNR

Larry Martin, Real Estate/Facility Development

Investor FAQ:

Does International Milk Bank have safety guidelines in place to assure the donor milk is safe?

International Milk Bank has built in Cornerstone Measures of Safety for new donor moms, beginning with an in-depth medical history and a survey addressing medical, social, lifestyle and nutritional questions, followed by an interview.

- Laboratory blood tests are scheduled to screen prospective donors for HIV I and II, Hepatitis B (HbsAg), Hepatitis C (HCV), RPR (syphilis), HTLV I and II (Human T-Lymphotrophic Virus), T. Cruzi and West Nile Virus. All donors are tested every five months and approved donors can donate for up to one year.
- Drug testing screens potential donors for amphetamines, barbiturates, benzodiazepines, cannabinoids (marijuana), cocaine, methadone (dolphin), opiates (codeine, morphine only), and propoxyphene and phencyclidine (PCP).
- Each donor is required to obtain permission in writing from her physician and from her baby's pediatrician to participate in the International Milk Bank program.



How does International Milk Bank protect against infection, disease and contamination of human breast milk purchased from OnlyTheBreast?

International Milk Bank's safety protocols closely follow the extensive testing, controls, and considerations outlined in the FDA Working Group on Banked Human Milk. Our proprietary technology and processes deliver a consistently high standard of safety, quality and consistency in our human milk products:

- All donations are shipped frozen, packed in pouches and an insulated cooler according to International Milk Bank's instructions and are delivered by next-day air.
- Each shipment is received and quarantined, visually inspected, bar-coded for donor identification and then stored in a -10°F commercial walk-in freezer for required testing.
- All milk is subjected to drug screening and bovine protein testing to assure a donor has not replace her breast milk with cows milk and each donation correctly matches the assigned donor bar code.

How does International Milk Bank sterilize and bottle its product?

Closely following an established chain of product safety, International Milk Bank processes and tests each batch for a full microbiological panel including Aerobic count, B. cereus, Escherichia coli, Salmonella, Pseudomonas aeruginosa, coliforms, Staphylococcus aureus, yeast and mold.

A full nutritional analysis is performed assuring product standards.



International Milk Bank's advanced milk-sterilization process ensures milk safety and market sustainability. All donor milk is handled according to FDA's Pasteurized Milk Ordinance and in accordance with HMBNA specifications in our certified GMP plant.

Final testing is completed as each lot is quarantined until all data are reviewed, verified, and approved by International Milk Bank quality assurance teams.

IMB uses BPA free sterile polypropylene or high-density polyethylene bottles to house their milk. Each bottle is labeled with appropriate nutritional values and a 'use by' date and lot number.

Bottled milk is packaged according to product line, volume, and case size and stored for shipping at room temperatures at or below 65 degrees.

How does International Milk Bank market its safe, non-refrigerated sterilized donor milk?

International Milk Bank has a strong advisory board with expertise in medical and in bio-science fields. We have also developed a wide network of relationships in the health-care industry, including award-winning Novation; a leading healthcare supply chain providing visibility and reach to over 2,911 hospitals nationwide and has an exclusive alliance with 54 Children's hospital associations.

Hospitals save tens of thousands a year by purchasing through GPO's. Novation has asked International Milk Bank to become a supplier of safe human donor milk. This opens a huge supply chain for International Milk Bank to supply.

International Milk Bank has received letters of intent to purchase from Renown Medical Center, and Dignity Health, formerly known as Catholic Health Care. Dignity health is formerly known as Catholic Health Care is the 5th largest hospital system representing 42 hospitals on the West Coast alone, we are presently building a marketing campaign to educate and supply neonatal intensive care units nationwide.

Because International Milk Bank has the ability to meet demands totaling more than 72,000,000 ounces, we are making our standardized and non-refrigerated products available to mothers through the following channels:

- Orders for direct purchases can be placed on our Web site.
- Hospitals can order milk, both for inpatients and upon discharge for outpatients
- GHX healthcare supply chain management allows International Milk Bank, as a provider, to streamline ordering and payment for hospitals
- Physician endorsement and prescription of human milk provides reimbursement under health care plans.

International Milk Bank supports its marketing with earned and paid media. The company drew recent favorable mention in The New York Times, for instance, and its sophisticated Web presence already places it at the top of search-engine results for users looking to purchase breast milk.

What strategy does International Milk Bank employ to protect its share of the market?

The most compelling answer is that International Milk Bank has exclusive rights to the largest supply of donor human milk.

International Milk Bank has an exclusive long-term contract with OnlytheBreast.com to supply all donor milk which provides International Milk Bank with the lion's share of human breast milk, and that milk supply will only be increasing.

International Milk Bank's proprietary technology ensures that our milk sets the new standard for all milk. Our products are free of diseases such as Bacillus Cereus, a high heat resistant bacteria, which causes conditions that presents a fatal risk to pre-term babies. Other milk banks that have spent millions on required FDA clinical trials proving and/or using the pasteurization process cannot provide this assurance to mothers and healthcare professionals.

Because International Milk Bank status is a milk bank and uses proprietary methodology; a protein-rich milk for premature infants, there is no regulating "event" or "process" that would require FDA clinical trials which means International Milk Bank is able to take their product straight to market.

Our strategic partner, **Cleanroom Management Associates Inc.**, is well established in the industry and the FDA. Cleanroom Management Associates brings the expertise that further mitigates any risk related to our facility. However, International Milk Bank is raising the bar by establishing an industry standard with its Pharmaceutical Grade Processing plant. Simply put, our certified CGMP facility and proprietary process exceeds FDA or any other governmental legislation requirements. And because many international countries require certification before sales can begin. IMB can easily support their purchasing needs. .

Furthermore, our team has the experience. Our CEO, Glenn Snow, is an industry expert, who understands the market and the competition. Our General Manager, Michael Shirley, established and managed Prolacta's processing operations. IMB not only has the supply, and the solution, we have the team to capture the majority of the market share for donor human milk.